Breast Cancer Clinical Trial
Official title:
Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment
The purpose of this study is to examine relationships among lifestyle behaviors (i.e.,
physical activity, sleep), cognitive function (i.e., memory, processing speed, and executive
function), and quality of life in breast cancer patients and survivors across time. The
investigators will compare the strength of these relationships across age cohorts and time
since treatment and diagnosis. Participants will complete a battery of questionnaires and a
set of cognitive tests on an iPad app specifically tailored for this study. A subset of
participants will also wear an accelerometer for seven days. Data will be collected at
baseline and 6-month follow-up.
This research is critical to identifying potentially important approaches to improving health
outcomes and quality of life in breast cancer patients and survivors. Previous research
provides evidence of the influence of lifestyle behaviors on cognition and quality of life in
healthy aging populations. However, despite data indicating cancer's negative impact on
lifestyle behaviors, cognition, and quality of life, very few studies have investigated
interactions among these factors in cancer patients and survivors.
Interested individuals will visit the ReFLECT Study website (www.reflectstudies.org) to learn
more about the study and receive instructions on how to participate. Individuals will be
instructed to create a username (email address) and password for BrainBaseline©
(www.BrainBaseline.com; Digital Artefacts, Iowa City, IA). While BrainBaseline© is a
commercially available mobile app, a version specifically tailored for this study will be
used. The website directions will include information on how to download the BrainBaseline©
iPad app (for ReFLECT) from the iTunes store. Each time a participant closes and reopens the
iPad app, she will be required to enter her BrainBaseline© username and password. Upon
opening the iPad app for the first time, the individual will be asked to confirm their
eligibility for the study. If eligible, the individual will proceed to the consent form.
Participants will electronically sign the Institutional Review Board-approved informed
consent form before completing a battery of questionnaires assessing demographics, medical
history, physical activity, sedentary behavior, sleep, fatigue, quality of life, satisfaction
with life, depressive symptoms, and perceived memory. Individuals cannot view the
questionnaires until they have electronically signed the consent form. Participants will also
be asked to complete a set of ten evidence-based cognitive tests assessing attention, speed
of processing, and executive function. Descriptions of the tests are available at
www.BrainBaseline.com/assessments. The questionnaires are expected to take approximately 45
minutes and the cognitive tests are expected to take approximately 60 minutes to complete.
Participants will be instructed to complete the questionnaires and cognitive tests within two
weeks of signing the consent form. The onscreen instructions and consent form will also
notify participants that a) they do not have to complete either the questionnaires or the
cognitive tests in one sitting, but can return to them during the course of the week, and b)
they can move back and forth between the questionnaires and cognitive tests (i.e., do not
need to finish one section before moving to the next). Reminder emails will be sent on days 7
and 10 to remind participants to complete assessments.
A subset of participants who volunteer to do so will also wear an accelerometer for 24 hours
per day for 7 consecutive days to objectively measure activity levels and sleep quality.
Individuals will be asked if they are willing to be contacted to wear the accelerometer via
the consent form. Only those individuals who check the box agreeing to be contacted by the
research team will be contacted to wear the accelerometer (see consent form). Participants
will be contacted via email and instructed to reply to the researcher by phone or email with
their mailing address. The accelerometer, instructions for wear, a Record of Use form, and a
postage-paid return envelope will be mailed to participants who agree to wear the monitor.
Mailing labels from postage-paid return envelopes will be disposed of after accelerometers
have been returned and recorded. The accelerometer will be worn during women's daily life on
a normal week; therefore, minimal additional time committed to research activities will be
required of participants. No contact will be solicited with participants over the course of
the 6-month study period.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |